Biohaven Ltd. (NYSE:BHVN) shares are trading up more than 8% on Thursday as investors react to new early clinical oncology data, even as the healthcare sector is down 1.8% (the worst of 11 sectors) and the S&P 500 is off 0.23%.
The company reported Phase 1 results for BHV-1530, an FGFR3-directed antibody-drug conjugate using a proprietary TopoIx payload.
The data showed six of 10 responses in FGFR3-altered cancers at doses of at least 3.3 mg/kg, including three of five in urothelial cancer and three of three in HPV-positive head and neck squamous cell carcinoma. Nine out of 10 had a tumor reduction.
The company said it has completed an FDA Type C meeting in the fourth quarter of 2026 and expects to start a pivotal study as early as the first half of 2027, beginning in urothelial cancer with an eye toward potential accelerated approval.
BHVN Technical Analysis: Trend, Momentum And Key Levels
From a longer-term trend view, the stock is still holding a constructive structure after the golden cross in July (50-day SMA above the 200-day SMA), and it’s now trading 12.9% above the 200-day SMA ($12.37).
Near term, it’s mixed: shares are 4.6% below the 20-day SMA ($14.64) and 1.1% below the 100-day SMA ($14.11), but 3.9% above the 50-day SMA ($13.44), which often acts like a "line in the sand" for swing traders.
Momentum looks more like a reset than a breakout: RSI is 50.51, which is neutral and suggests the stock isn’t stretched after recent swings.
RSI is a quick way to gauge whether buying or selling has become overheated; here it implies room for follow-through if buyers defend support and reclaim the short-term averages.
- Key Resistance: $15.00 — a round-number area that can cap rebounds, especially with the 20-day SMA ($14.64) sitting just below it.
- Key Support: $13.50 — a nearby pivot area that’s also close to the 50-day SMA ($13.44), making it a practical level to watch for dip-buying interest.
How Biohaven Ranks On Momentum And Market Factors
Below is the Benzinga Edge scorecard for Biohaven, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 91.47) — The stock is showing strong relative strength versus the broader market.
The Verdict: Biohaven’s Benzinga Edge signal reveals a momentum-driven story, with price action currently speaking louder than traditional factor grades.
For longer-term traders, the key is whether the stock can build on this burst of strength by holding the $13.50 area and working back above the $15.00 ceiling.
BHVN Stock Price Activity: Biohaven shares were up 8.22% at $13.96 at the time of publication on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





